Oryzon announces hope-2 clinical trial; sponsorship of pms boi

Written By Brandonne Rankin

Oryzon announced the launch of its HOPE-2 clinical trial in the EU today. The trial will test the safety and efficacy of its drug, vafidemstat, in treating PMS. The company also voiced support for and sponsorship of CureSHANK’s first-ever burden of illness study. Get the full story here:

Brandonne Rankin
Next

CURESHANK COMMUNITY NEWS: September 2025